Friedberg @ 01:19:54Inconclusive
healthscience
A first FDA-approved human drug whose primary mechanism of action is Yamanaka-factor-based cellular rejuvenation (reprogramming cells using modified OSKM-like proteins) will be approved in the United States roughly 7–12 years from 2025, i.e., between 2032 and 2037.
Just knowing the clinical path there, I would say we're probably somewhere between 7 and 12 years away.View on YouTube
Explanation
The prediction states that “a first FDA-approved human drug whose primary mechanism of action is Yamanaka-factor-based cellular rejuvenation … will be approved in the United States roughly 7–12 years from 2025, i.e., between 2032 and 2037.” That approval window (2032–2037) has not started yet as of the current date (November 30, 2025). Therefore, it is too early to know whether such a drug will in fact be approved in that time frame. No amount of current web or scientific literature search can confirm or falsify an approval that is explicitly predicted for future years. Hence, the correct status is inconclusive (too early).